Serina Therapeutics Files 8-K
Ticker: SER · Form: 8-K · Filed: Jul 29, 2025 · CIK: 1708599
| Field | Detail |
|---|---|
| Company | Serina Therapeutics, Inc. (SER) |
| Form Type | 8-K |
| Filed Date | Jul 29, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, financials
TL;DR
Serina Therapeutics dropped an 8-K with Reg FD and financials - check it out.
AI Summary
Serina Therapeutics, Inc. filed an 8-K on July 29, 2025, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as AgeX Therapeutics, Inc. until June 6, 2017, is incorporated in Delaware and headquartered in Huntsville, Alabama.
Why It Matters
This filing provides important updates on Serina Therapeutics' regulatory disclosures and financial statements, which are crucial for investors to assess the company's current standing and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial statements and exhibits, not indicating any immediate material adverse events.
Key Players & Entities
- Serina Therapeutics, Inc. (company) — Registrant
- AgeX Therapeutics, Inc. (company) — Former company name
- July 29, 2025 (date) — Date of report
- Huntsville, Alabama (location) — Principal executive offices
FAQ
What is the primary purpose of this Form 8-K filing?
The primary purpose of this Form 8-K filing is to report a Regulation FD Disclosure and to file Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on July 29, 2025.
What was Serina Therapeutics, Inc. formerly known as?
Serina Therapeutics, Inc. was formerly known as AgeX Therapeutics, Inc.
In which state is Serina Therapeutics, Inc. incorporated?
Serina Therapeutics, Inc. is incorporated in Delaware.
What is the business address of Serina Therapeutics, Inc.?
The business address of Serina Therapeutics, Inc. is 601 Genome Way, Suite 2001, Huntsville, Alabama 35806.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 29, 2025 regarding Serina Therapeutics, Inc. (SER).